NCT02979366Phase I, international, multicentre, open-label, non-randomised, non-comparative study of intravenously administered S64315, a Mcl-1 inhibitor, in patients with Acute Myeloid Leukaemia (AML) or Myelodysplastic Syndrome (MDS)
MD Anderson Study Status
S64315 once a week, S64315 twice a week
The CL1-64315-001 study is a phase I, international, multicentre, open-label, non-randomised, non-comparative study. This study is designed in two parts: one part for dose escalation, one part for dose expansion.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Acute Myeloid Leukaemia (AML), Myelodysplastic Syndrome (MDS)
For general questions about clinical trials:
Due to our response to COVID-19, all blood donations at MD Anderson
Blood Donor Center locations are being held by appointment only.